Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
Authors
Keywords
Second-line therapy, Biliary tract cancer, Capecitabine, Mitomycin C, Thymidylate synthase, Thymidine phosphorylase
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 77, Issue 1, Pages 109-114
Publisher
Springer Nature
Online
2015-12-10
DOI
10.1007/s00280-015-2919-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Second-line chemotherapy in patients with biliary tract cancer.
- (2017) G. Brandi et al. JOURNAL OF CLINICAL ONCOLOGY
- P-147 * Outcome of second-line chemotherapy (CT2) after first-line CT (CT1) with platinum plus gemcitabine in advanced biliary tract cancer (aBTC): is it worthwhile?
- (2015) L. Fornaro et al. ANNALS OF ONCOLOGY
- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study
- (2014) R. Buzzoni et al. ANNALS OF ONCOLOGY
- Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
- (2014) L Fornaro et al. BRITISH JOURNAL OF CANCER
- Second-line therapy in advanced biliary tract cancer: What should be the standard?
- (2013) Stefano Cereda et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A Pilot Study to Investigate the Role of Thymidylate Synthase as a Marker of Prognosis for Neoadjuvant Chemotherapy in Gastric and Gastro-Oesophageal Junction Adenocarcinoma
- (2013) A. Mirza et al. Gastroenterology Research and Practice
- Biliary tract carcinomas: From chemotherapy to targeted therapy
- (2012) Donatella Marino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed
- (2011) Chung-Yu Chen et al. LUNG CANCER
- Imatinib Mesylate for Palliative Second-Line Treatment of Advanced Biliary Tract Cancer: A Bicentric Phase II Study
- (2011) Annekathrin Roth et al. ONKOLOGIE
- Thymidine synthase, thymidine phosphorylase and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
- (2010) S Lee et al. BRITISH JOURNAL OF CANCER
- Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
- (2010) Su Jin Lee et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Role of dihydropyrimidine dehydrogenase and thymidylate synthase expression in immunohistochemistry of intrahepatic cholangiocarcinoma
- (2010) Masaaki Nishi et al. HEPATOLOGY RESEARCH
- Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study
- (2010) Atul Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer
- (2008) C. Andreetta et al. ANNALS OF ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now